By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Shield Therapeutics 

Abbey House
Wellington Way
Weybridge       United Kingdom
Phone: +44 (0)1932-268436 Fax: +44 (0)870 458-6523



Company News
Shield Therapeutics Announces The Publication Of The AEGIS Feraccru Phase 3 Pivotal Trial Manuscript In The Inflammatory Bowel Disease Journal 1/9/2015 11:47:33 AM
Shield Therapeutics Announces The Acceptance For Review By The European Medicines Agency Of The Marketing Authorisation Application For Feraccru® 1/7/2015 7:49:53 AM
Shield Therapeutics Announces Acceptance Of ST10 Abstract For Presentation At ECCO Congress 2014 2/4/2014 12:45:28 PM
Shield Therapeutics' ST10 Delivers Robust Results Meeting Both Primary And Secondary Endpoints In The Pivotal AEGIS Phase 3 Program For The Treatment Of Iron Deficiency Anemia In Inflammatory Bowel Disease 1/7/2014 6:54:16 AM
Shield Therapeutics Release: FDA Grants Approval Of IND To Commence A Phase 3 Pivotal Study For ST10 For The Treatment Of Iron Deficiency Anemia In Chronic Kidney Disease 12/16/2013 8:44:15 AM
Shield Therapeutics Files Investigational New Drug Application For ST10 For The Treatment Of Iron Deficiency In Chronic Kidney Disease 11/12/2013 9:03:14 AM
Shield Therapeutics to Attend Biotechnology Industry Organization (BIO)-Europe® 2013 10/23/2013 6:43:54 AM
Shield Therapeutics Completes Recruitment to Pivotal Phase 3 Programme for Treatment of Iron Deficiency 6/24/2013 11:19:11 AM
Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10 10/12/2011 5:55:21 AM
Shield Therapeutics Raises EUR8.2 Million From Inventages Venture Capital Via Series A Institutional Round 6/1/2011 6:47:48 AM